Bristol Myers Squibb receives CHMP Approval Recommendation for Nivolumab (Opdivo®) plus Chemotherapy for the neoadjuvant Treatment of resectable non-small cell Lung Cancer with PD-L1 Expression=1% in Patients at high Risk of Recurrence-MedSci.cn

Bristol Myers Squibb receives CHMP Approval Recommendation for Nivolumab (Opdivo®) plus Chemotherapy for the neoadjuvant Treatment of resectable non-small cell Lung Cancer with PD-L1 Expression=1% in Patients at high Risk of Recurrence

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2023; 46 (7-8): 344

科室
- - 订阅+
  - 更多科室
工具
服务